Roadmapping 5.0 Technologies in Agriculture: A Technological Proposal for Developing the Coffee Plant Centered on Indigenous Producers' Requirements from Mexico, via Knowledge Management

The coffee plant, with more than 40 billion shrubs, 9 million tons of grains produced, and 80% of its production accounted for by small-scale producers, has been severely damaged since the emergence of Hemileia vastatrix and Hypothenemus hampei. Despite technological support, these pests have caused 20% to 40% production losses, a 50% to 60% deficit in performance, and a cost of between USD 70 million and USD 220 million to the world economies, which forces us to rethink actions centered on people as the key elements to develop appropriate solutions. For this, the present study presents a technological proposal centered on small indigenous coffee producer requirements for introducing Industry 5.0 technologies, considering roadmapping, knowledge management, statistical analysis, and the social, productive, and digital contexts of five localities in Mexico. The results show a correlation between monitoring and control, soil analysis, the creation of organic fertilizers, accompaniment, and coffee experimentation, as the actions to be implemented, proposing the introduction of a mobile application; sensors, virtual platforms, dome-shaped greenhouses, and spectrophotometric technology as relevant technologies centered on indigenous coffee producers' requirements. This study is important for policymakers, academics, and producers who wish to develop strategies centered on people in Mexico and the world.

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

To evaluate the efficacy and toxicity of irinotecan (CPT-11) in combination with raltitrexed as first-line treatment of advanced colorectal cancer (CRC). A total of 91 previously untreated patients with advanced CRC and measurable disease were enrolled in this phase II study. The median age was 62 years (range 31–77); male/female 54/37; ECOG performance status was 0 in 50 patients (55%), one in 39 (43%) and two in two (2%). Treatment consisted of CPT-11 350 mg m⁻² in a 30-min intravenous infusion on day 1, followed after 30 min by a 15-min infusion of raltitrexed 3 mg m⁻². Measurements of efficacy included the following: response rate, time to disease progression and overall survival. Of the 83 evaluable patients valuable to objective response, there were five complete responses (6%) and 23 partial responses (28%), for an overall response rate of 34% (95% CI: 25.9–46.5%). In all, 36 patients (43%) had stable disease, whereas 19 (23%) had a progression. The median time to progression was 11.1 months and the median overall survival was 15.6 months. A total of 487 cycles of chemotherapy were delivered with a median of five per patient. Grade 3–4 WHO toxicities were as follows: diarrhoea in 13 patients (15%), nausea/vomiting in four (4%), transaminase increase in six (7%), stomatitis in two (2%), febrile neutropenia in three (3%), anaemia in five (6%) and asthenia in three (3%). The combination CPT-11–raltitrexed is an effective, well-tolerated and convenient regimen as front-line treatment of advanced CRC.